| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $3.5M | +0.4% | +53.6% |
| SG&A Expense | $653K | +21.4% | +49.4% |
| Operating Income | -$4.2M | -3.2% | -53.0% |
| Net Income | -$4.2M | -3.1% | -55.6% |
| EPS (Basic) | -$0.30 | +0.0% | -50.0% |
| EPS (Diluted) | -$0.30 | +0.0% | -50.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $3.8M | +21.8% | -34.6% |
| Total Assets | $3.8M | +21.8% | -34.6% |
| Current Liabilities | $1.6M | -3.8% | +92.5% |
| Total Liabilities | $1.6M | -3.8% | +92.5% |
| Stockholders' Equity | $2.2M | +51.8% | -56.1% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$6.7M | — | — |
| Financing Cash Flow | $6.5M | — | — |